BioSpace News Archive

President Donald Trump pledged a vaccine for the novel coronavirus that causes COVID-19 would be available by the end of the year. The remarks were made during an acceptance speech for the Republican Party presidential nomination Thursday night.

One day after Abbott secured Emergency Use Authorization for its $5 coronavirus test, the White House awarded the company a $750 million contract to deliver 150 million Abbott BinaxNOW COVID-19 Ag Card Point of Care (POC) SARS-CoV-2 diagnostic tests.

A new study published in the August 26 edition of Science Advances shows that the effectiveness of a two-pronged Type 2 diabetes treatment improves when drugs are linked by a heat-sensitive tether.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 28, 2020.

EcoHealth had already developed a partnership with a WIV laboratory in Wuhan, China, under a five-year NIH grant. It was expected to run through 2024 but was canceled in April.

According to data from Phase I clinical trials, a new breast cancer drug developed by researchers at the University of Illinois Chicago can potentially stop disease progression without toxicity.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

- World-first technology developed by ROQU Group to protect society, economy, and jobs - Irish trial commences with national partners in healthcare, agriculture, education, childcare, logistics, entertainment, and other sectors - Irish-engineered digital platform, in partnership with advanced diagnostics, delivers test results within 15 minutes, allowing businesses to operate

Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will announce its interim results for the six months ended 30 June 2020 on 10 September 2020.